Allergan
Executive Summary
NDAs submitted for Restasis (ophthalmic cyclosporine) for moderate-to-severe dry eye, and Abrevia (ophthalmic nedocromil) for allergic conjunctivitis. Restasis, licensed from Novartis, is the first therapy for the indication other than artificial tears, Allergan said. The NDA was submitted late in March. Abrevia, licensed from Rhone-Poulenc Rorer, was submitted in February. In addition, a supplemental PLA for Botox was submitted for cervical dystonia in March